appropriate level of sedation. Initial infusion rates of up to 20 mllminute of the 0.8070 solution have been recommended,3 and maintenance infusions of up to 3 litres per 24 hours have been found to be necessary. 6 However, the infusion of this amount of intravenous fluid, particularly in some intensive care patients, may not be desirable. As the use of a more concentrated solution of chlormethiazole through a central venous catheter would obviate this volume problem, it was decided to conduct a preliminary study using anaesthetised greyhounds.
The 0.8070 solution of chlormethiazole ethanedisulphonate (hereafter referred to as chlormethiazole) was introduced after reports of haemolysis with the intravenous use of 2070
Anaesthesia and Intensive Care, Vo/. IX, No. 1, February, 1981 solutions. 7 • 8 ,9 As peripheral veins had been used in these patients, it was decided to examine the effects on haemolysis of infusing concentrated chlormethiazole solutions into central veins in anaesthetised greyhounds. Control experiments were performed in which hyperosomolar dextrose solutions were infused at the same rates as the concentrated chlormethiazole solutions. The dextrose solutions were adjusted to the same pH as the chlormethiazole solutions. Loss of chlormethiazole into the plastic infusion sets was also examined.
MATERIALS AND METHODS
Approximately one gram of chlormethiazole was infused over each half hour into ten greyhounds weighing between 26 and 32 kg. Anaesthesia was induced with sodium thiopentone (10-15 mg/kg), a cuffed endotracheal tube was inserted, and anaesthesia was maintained with 1070 halothane in air and intermittent positive pressure ventilation. In six dogs two catheters (model 200/490/060, Portex Ltd., Hythe, K~nt, U.K.) were placed with the aid of an image intensifier in the inferior vena cava via a surgically exposed femoral vein, one at the level of the 4th lumbar vertebra (L4), and one at the level of the 12th thoracic vertebra (T12). In the four control dogs, an additional catheter was placed at the level of T12 for the dextrose infusions. Samples were taken every five minutes from the catheter at L4 for free plasma haemoglobin estimation, and every 15 minutes for blood chlormethiazole estimation. The chlormethiazole and dextrose solutions were infused at the level of T12.
In six dogs, after a 30 minute control period (omitted in one dog), approximately one gram of chlormethiazole was infused during each half hour, using successively, 0.8%,1.2%,2%, 5%, 10%, and 20% solutions. As a constant rate infusion pump (model 94, Harvard Apparatus, Millis, Massachusetts, U.S.A.) was used, the exact amount of chlormethiazole infused each half hour was dictated by available pump speeds (Table 1) . In four dogs, after a half hour control period, one gram of chlormethiazole was infused each half hour as a 0.8070 solution, and, half an hour after the start of the chlormethiazole infusion, dextrose solutions of 5, 10, 20, 40 and 70070 were infused into the additional catheter over successive half hours at the same rates, respectively, as the 1.2,2, 5, 10 and 20070 chlormethiazole solutions. The dextrose solutions were adjusted to the same pH as the chlormethiazole solutions by the addition of hydrochloric acid ( Table 1) . The dextrose solutions were significantly more hypertonic than the corresponding chlormethiazole solutions (Table 2) .
In four dogs the loss of chlormethiazole into the infusion syringes and tubing was examined. Each solution was drawn up into a 50 cc syringe and infused through three 60 cm Portex catheters in series; taps were placed between the syringe and the first catheter, between the first and second catheter, and between the second and third catheter. Before each infusion, the series of catheters and taps were accurately preloaded with the appropriate chlormethiazole solution, and samples for chlormethiazole assay were taken from each tap immediately before and immediately after each half hour infusion.
Plasma haemoglobin concentrations were determined spectrophotometrically by the method of Crosby and Furth.lO Blood was collected into dipotassium ethylenediaminetetra-acetate with care to avoid haemolysis on sampling. Cellular components were centrifuged lightly (800 x G for 2 min) out of suspension within 30 minutes of sampling. Plasma samples were stored at -20 QC if not analysed within four hours.
The chlormethiazole determinations were by the gas chromatographic method of Mather and Tucker, 11 using a nitrogen detector in place of a flame ionization detector. Bromethiazole was used as an internal standard. Blood concentrations are expressed as chlormethiazole base (8. The concentration of each chlormethiazole infusion was checked at three sites in the infusion apparatus, both before and after each injection, as described above, by a modification of the high-performance liquid chromatographic method of Austin and Mather,12 using an octadecylsilane column for reverse-phase chromatography with detection by ultra-violet absorbance at 265 nm.
The pH of the concentrated dextrose solution was adjusted to that of the equivalent chlormethiazole solution (Table 1) by the addition of IM hydrochloric acid.
RESULTS
For the dogs that received the dextrose solutions (Figure 1) , and for the control period for the six dogs that received the concentrated chlormethiazole solutions (Figure 2 ), the free plasma haemoglobin remained at less than 200 mg/litre. These amounts probably reflect mechanical rather than drug-induced lysis of red cells, since under undisturbed conditions, haemoglobin does not appear in blood plasma in measurable concentrations. In each of the dogs that received the concentrated chlormethiazole solutions (Figure 2 ), rapid progressive haemolysis occurred. This started with the 5070 solution in three dogs (dogs 7, 8 and 9) with the 10070 solution in two dogs (dogs 6 and 10), and with the 20070 solution in one dog (dog 5). The plasma haemoglobin levels increased progressively in these dogs to between 900 and 4,000 mg/litre. Blood chlormethiazole levels in all dogs ranged from 25-150 mg/l.
Approximately 20070 of the chlormethiazole in the 0.8070 solution and 10070 of that in the 1.2070 solution, was lost into the giving apparatus. There was no significant loss when the more concentrated solutions were subsequently infused through the same tubing (Table 3) . There was a 100% recovery of the 2, 5, 10 and 20% solutions at Taps I, 2 and 3, both before and after the infusion. Tap I: Situated between infusion syringe and first 60 cm catheter. Tap 2: Situated between the first and second 60 cm catheter. Tap 3: Situated between the second and third 60 cm catheter.
DISCUSSION
The standard clinical solution of chlormethiazole (0.8070) available for clinical use did not cause haemolysis. Rapid progressive haemolysis occurred when concentrated solutions of chlormethiazole were infused into the inferior vena cava of six greyhounds. No haemolysis occurred when hyperosmolar dextrose solutions of the same pH as the chlormethiazole solutions were infused into dogs with the same chlormethiazole blood levels. The experimental design was chosen because the blood flow past the infusion catheter tip was similar to or slightly lower than 
Control
that in an average resting patient. This is because central lines in man are usually placed in the superior vena cava rather than the right atrium, and because the cardiac output of a greyhound anaesthetised with 1 % halothane in air is about 3-4 litres/minute. 13 The extent to which haemolysis occurred was not related to the concentration at which haemolysis first started (for example, in dog 9, although haemolysis started with an infusion of a 5% solution, free plasma haemoglobin only rose to 900 mg/litre with the 20% solution), nor was it related to chlormethiazole blood levels. In fact, the dog with the least degree of Tables 1 and 2. haemolysis with the 20070 chlormethiazole solution had the highest blood chlormethiazole concentration (dog 8). However, once haemolysis started, it became rapidly progressive with the infusion of increasing concentrations of chlormethiazole.
Chlormethiazole may be lost into infusion syringes and tubing. This was confirmed in this study, as approximately 20% of the 0.8% solution and 10% of the 1.2% was lost. It has been shown that this effect is virtually abolished if the solution is infused at a low pH at which nearly all the chlormethiazole is present in ionized form as the edisylate salt (personal communication, Moore RG, Astra Pharmaceuticals, Aust.). This was confirmed as there was insignificant loss of the more concentrated solutions which were infused at a low pH (Tables 1 and 3 ).
In conclusion, it would seem that the current practice of using the 0.8% solution is justified. A 2% solution of chlormethiazole should not be available for intravenous infusion in man, even into a central vein, until further studies have been done. Loss of chlormethiazole into the infusion apparatus should be taken into consideration when undertaking quantitative studies.
